Navigation Links
Cardinal Health Releases New Tool to Combat MRSA Infections in Hospitals
Date:10/30/2007

MRSA Scorecard Provides Hospital-Wide View of MRSA Infections

DUBLIN, Ohio, Oct. 30 /PRNewswire-FirstCall/ -- Cardinal Health, a global provider of products and services that improve the safety and productivity of health care, today announced a new service to help hospitals combat methicillin-resistant staphylococcus aureus (MRSA) infections that are responsible for an estimated 94,000 life-threatening conditions and 18,650 deaths annually in the U.S.(1)

Cardinal Health is deploying a new MRSA Scorecard to hospitals that monitor infections using the company's MedMined(TM) services. The new scorecard provides a hospital-wide view of MRSA, allowing infection control practitioners to track the types and locations of MRSA infections throughout the hospital. The MRSA Scorecard uses Cardinal Health's patent-pending Nosocomial Infection Marker (NIM) methodology, which allows hospitals to identify patients who have tested positive for the bacteria and distinguish between those who likely acquired the infection in the hospital. Through this real-time view, hospitals can rapidly dispatch resources to limit the spread of infections.

The MRSA scorecard is available to all hospitals using MedMined(TM) services and will be offered free of charge for four months through a sponsorship program from BD (Becton, Dickinson and Company).

"The MRSA Scorecard will help hospitals make evidence-based decisions about the most appropriate way to respond to MRSA in their facilities," said Patrick Hymel, MD, vice president and medical director for Cardinal Health's MedMined(TM) services. "This new tool enables a comprehensive and consistent approach to preventing these dangerous infections."

Cardinal Health provides nearly 250 major U.S. hospitals with automated electronic infection prevention surveillance and management systems designed to identify health care associated infections (HAIs) in real time, enabling immediate interventions to prevent subsequent adverse patient events.

HAIs affect one in 20 patients admitted each year. According to the Centers for Disease Control and Prevention (CDC), eradicating MRSA has become a national priority -- one that requires all health care facilities and agencies to assume responsibility. A recent national survey done by the Association for Professions in Infection Control and Epidemiology (APIC) indicates an estimated 46 per 1,000 patients are either infected or colonized with MRSA annually, a rate about 10 times greater than previous MRSA estimates.(2) As a result, most U.S. hospitals are in the process of designing and implementing aggressive infection prevention programs designed to stop the spread of MRSA in their health care institutions.

About Cardinal Health

Headquartered in Dublin, Ohio, Cardinal Health, Inc. (NYSE: CAH) is an $87 billion, global company serving the health care industry with products and services that help hospitals, physician offices and pharmacies reduce costs, improve safety, productivity and profitability, and deliver better care to patients. With a focus on making supply chains more efficient, reducing hospital-acquired infections and breaking the cycle of harmful medication errors, Cardinal Health develops market-leading technologies, including Alaris(R) IV pumps, Pyxis(R) automated dispensing systems, MedMined(TM) data mining service and the CareFusion(TM) patient identification system. The company also manufactures medical and surgical products and is one of the largest distributors of pharmaceuticals and medical supplies worldwide. Ranked No. 19 on the Fortune 500 and No. 1 in its sector on Fortune's ranking of Most Admired firms, Cardinal Health employs more than 40,000 people on five continents. More information about the company may be found at http://www.cardinalhealth.com.

(1) "Invasive Methicillin-Resistant Staphylococcus aureus Infections in

the United States," The Journal of the American Medical Association,

Vol. 298 No. 15, October 17, 2007.

(2) Association for Professionals in Infection Control and Epidemiology.

(2007). Methicillin resistant Staphylococcus aureus (MRSA) study

results. http://www.apic.org/Content/NavigationMenu/ResearchFoundation

/NationalMRSAPrevalenceStudy/APIC_MRSA_STUDY_EXEC.pdf


'/>"/>
SOURCE Cardinal Health
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Controlling the Spread of Healthcare Associated Methicillin Resistant Staphylococcus aureus Requires Active Surveillance
2. Largest National U.S. Healthcare Facility MRSA Study Reveals Infection Rates Eight Times Greater Than Previous Estimates
3. Nationwide MRSA Prevalence Study to Demonstrate Full Scope of Superbug Threat Facing U.S. Healthcare Facilities and Patients
4. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
5. Data Showing that ReGens Colostrinin Supports Healthy Cognitive Function Presented at the 2007 International Congress on Natural Medicine in Australia
6. Antidepressant Use May Boost Fracture Risk, From Harvard Womens Health Watch
7. FDLI 50th Annual Meeting Heralds New ERA in Healthcare Innovations, FDA Regulations
8. New Data On the Probiotic Strain Bifantis Shows Anti-Inflammatory Properties and Increased Health Benefits
9. Actilyse (alteplase) Recommended by National Institute for Health and Clinical Excellence for Treatment of Acute Ischaemic Stroke
10. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
11. Eighty-one Percent of U.S. Adults say that Birth Control Pills and Procedures Should Be Covered by Health Insurance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... Research and Markets has announced the addition of the ... Market and Increasing Usage of Complex Biologics during the Forecast Period" ... ... 20 Billion in 2015 to around USD 26 Billion by 2020. ... by Rapidly Expanding Injectables Market and Increasing Usage of Complex Biologics ...
(Date:4/20/2017)... April 20, 2017  AbbVie (NYSE: ABBV), a ... (n=145/146) of chronic hepatitis C virus (HCV) infected ... 6 and compensated cirrhosis (Child-Pugh A) achieved sustained ... ) with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir ... seen following 12 weeks of G/P treatment without ...
(Date:4/20/2017)... , April 20, 2017 NeuroVive ... ("NeuroVive") today announced positive preclinical results demonstrating ... compound for non-alcoholic steatohepatitis (NASH), in an ... NV556 has previously shown similar ... model. Today, NeuroVive,s scientists present novel data ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... ... committed to raising awareness for Duchenne muscular dystrophy, and funding for Duchenne ... (cardiosphere-derived cells) Phase I/II HOPE clinical trial in Duchenne announced today. , ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... attempts to compare student test score performance for the 2015-16 school year across ... state’s voucher programs. Though it highlights important patterns in student test score performance, ...
(Date:4/25/2017)... Las Vegas, NV (PRWEB) , ... April 25, ... ... teeth can now choose a modern procedure that achieves results in a fraction ... orthodontist in Las Vegas, NV, with Significance Dental Specialists, now offers this ...
(Date:4/25/2017)... ... , ... Back Pain Centers of America (BPC), which connects people ... their area, announces the launch of a new and proprietary customer relationship management (CRM) ... reputable physicians to help them with back or neck pain and helps to match ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... analytics to its patient care management module. Using this new feature, sleep physicians ... has been initiated on continuous positive airway pressure (CPAP), oral, or other forms ...
Breaking Medicine News(10 mins):